Androgen receptor levels during progression of prostate cancer in the transgenic adenocarcinoma of mouse prostate model.

Murti, Krisna; Butler, Lisa M; Sakko, Andrew; Ricciardelli, Carmela; Mitto, Tina B; Octnick, Alexandra; Stahl, Jurgen; Tilley, Wayne D.
Artículo en Inglés | IMSEAR | ID: sea-148914

Documentos relacionados

  1. DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs.
  2. Genetic testing in prostate cancer management: Considerations informing primary care.
  3. Special Issue: "Novel Researches and Perspectives on Prostate Cancer".
  4. Shifting the paradigm in the management of early prostate cancer.
  5. Higher-order SPOP assembly reveals a basis for cancer mutant dysregulation.
  6. GraphPath: a graph attention model for molecular stratification with interpretability based on the pathway-pathway interaction network.
  7. Molecular mechanisms underlying the development of neuroendocrine prostate cancer.
  8. Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research.
  9. Antioxidative stress protein SRXN1 can be used as a radiotherapy prognostic marker for prostate cancer.
  10. Prostate Cancer: Insights into Disease Progression and Therapeutic Challenges.